文献速递肿瘤 PET/CT核素与放射性配体治疗

术中荧光成像能否识别所有病灶而术前核医学路径图被掩盖?

Can Intraoperative Fluorescence Imaging Identify All Lesions While the Road Map Created by Preoperative Nuclear Imaging Is Masked?
PubMed 文献 · J Nucl Med · 2019-11-11

研究评估荧光引导对前列腺癌前哨淋巴结(SN)的识别是否低于放射性引导。术前SPECT/CT创建路径图,比较ICG-99mTc-纳米胶体与游离ICG。荧光引导仅在40%杂交示踪剂组和20%游离ICG组患者中切除所有SN,整体低估了60%-80%患者的SN数量。

要点

  • 术前SPECT/CT路径图可识别更多异位前列腺SN。
  • 杂交示踪剂ICG-99mTc-纳米胶体优于游离ICG。
  • 荧光引导手术低估了60%-80%患者的SN数量。

核心结论

  • 荧光引导盆腔淋巴结手术在60%-80%的患者中低估了前哨淋巴结的数量。
  • 杂交示踪剂ICG-99mTc-纳米胶体表现优于游离ICG。

研究设计与样本

  • 患者接受前列腺内注射ICG-99mTc-纳米胶体(杂交示踪剂组)或99mTc-纳米胶体,后者术前注射游离ICG。
  • 术前行SPECT/CT创建路径图,术中先荧光引导识别SN,再行扩展盆腔淋巴结清扫(ePLND)。
  • 揭盲SPECT/CT图像后记录遗漏SN并在无并发症风险时切除。

主要发现

  • 术前SPECT/CT显示杂交示踪剂与99mTc-纳米胶体的SN识别率无差异。
  • 荧光引导仅在40%杂交示踪剂组和20%游离ICG组患者中切除所有SN。
  • 杂交示踪剂组75.9%、游离ICG组51.8%的术中切除SN仅由荧光引导完成。
  • ePLND中额外切除22个SN(杂交组7个,游离ICG组15个),揭盲后识别18个剩余SN(杂交组6个,游离ICG组12个)。
  • 游离ICG组离体标本显示14个经ePLND或揭盲后切除的SN含放射性但无荧光。

临床怎么用

  • 术前SPECT/CT路径图有助于识别异位前列腺SN,应作为手术规划参考。
  • 荧光引导可能遗漏部分SN,需结合放射性引导和扩展淋巴结清扫以确保全面切除。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Tracers can help visualize the lymphatic drainage patterns and sentinel nodes (SNs) of individual prostate cancer patients. To determine the role of nuclear medicine in surgical guidance, in particular the positional guidance of a SPECT/CT-based 3-dimensional imaging road map, in this process we studied to what extent fluorescence guidance underestimated the number of target lesions relative to radioguidance. Methods: SPECT/CT imaging was performed after intraprostatic tracer administration of either indocyanine green (ICG)-99mTc-nanocolloid (hybrid-tracer group) or 99mTc-nanocolloid to create a road map that depicted all SNs. Patients who received 99mTc-nanocolloid were injected with "free" ICG immediately before surgery. Before unmasking, fluorescence guidance was used for intraoperative SN identification. This was followed by extended pelvic lymph node dissection (ePLND). After unmasking of the SPECT/CT images, the number of missed SNs was recorded and their resection was pursued when there was no risk of intraoperative complications. Results: Preoperative SPECT/CT revealed no differences in the SN identification rate between ICG-99mTc-nanocolloid and 99mTc-nanocolloid. However, fluorescence guidance allowed intraoperative removal of all SNs in only 40% of patients in the hybrid-tracer group and 20% of patients in the free-ICG group. Overall, 75.9% of the intraoperatively resected SNs in the hybrid-tracer group and 51.8% of the SNs in the free-ICG group were removed solely under fluorescence guidance. During ePLND, 22 additional SNs were resected (7 in the hybrid-tracer group and 15 in the free-ICG group). After unmasking, 18 remaining SNs were identified (6 in the hybrid group and 12 in the free-ICG group). In the free-ICG group, ex vivo evaluation of the excised specimens revealed that 14 SNs removed under ePLND or after unmasking contained radioactivity but no fluorescence. Conclusion: The preoperative imaging road map provided by SPECT/CT enhanced the detection of prostate SNs in more ectopic locations in 17 of the 25 patients, and the hybrid tracer ICG-99mTc-nanocolloid was shown to outperform free ICG. Overall, fluorescence-guided pelvic nodal surgery underestimated the number of SNs in 60%-80% of patients.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Meershoek P, Buckle T, van Oosterom MN, et al. Can Intraoperative Fluorescence Imaging Identify All Lesions While the Road Map Created by Preoperative Nuclear Imaging Is Masked? J Nucl Med. 2019. PMID: 31712325. doi:10.2967/jnumed.119.235234

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。